{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:36:10Z","timestamp":1778056570541,"version":"3.51.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Orthop Surg Traumatol"],"DOI":"10.1007\/s00590-024-04071-w","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T10:02:38Z","timestamp":1723284158000},"page":"2881-2890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Filippo","family":"Migliorini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5327-3702","authenticated-orcid":false,"given":"Nicola","family":"Maffulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erlis","family":"Velaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"K\u00e4mmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Eschweiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf Krister","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"4071_CR1","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40520-020-01667-0","volume":"33","author":"F Salaffi","year":"2021","unstructured":"Salaffi F, Di Carlo M, Carotti M, Farah S, Giovagnoni A (2021) Frailty prevalence according to the survey of health, ageing and retirement in Europe-frailty instrument (SHARE-FI) definition, and its variables associated, in patients with symptomatic knee osteoarthritis: findings from a cross-sectional study. Aging Clin Exp Res 33:1519\u20131527. https:\/\/doi.org\/10.1007\/s40520-020-01667-0","journal-title":"Aging Clin Exp Res"},{"key":"4071_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12891-019-2521-4","volume":"20","author":"H Chen","year":"2019","unstructured":"Chen H et al (2019) The effects of a home-based exercise intervention on elderly patients with knee osteoarthritis: a quasi-experimental study. BMC Musculoskelet Disord 20:160. https:\/\/doi.org\/10.1186\/s12891-019-2521-4","journal-title":"BMC Musculoskelet Disord"},{"key":"4071_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cger.2010.03.001","volume":"26","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Jordan JM (2010) Epidemiology of osteoarthritis. Clin Geriatr Med 26:355\u2013369. https:\/\/doi.org\/10.1016\/j.cger.2010.03.001","journal-title":"Clin Geriatr Med"},{"key":"4071_CR4","first-page":"205","volume":"2","author":"B Heidari","year":"2011","unstructured":"Heidari B (2011) Knee osteoarthritis prevalence, risk factors, pathogenesis and features: part I. Casp J Intern Med 2:205\u2013212","journal-title":"Casp J Intern Med"},{"key":"4071_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/bor.0000000000000161","volume":"27","author":"KD Allen","year":"2015","unstructured":"Allen KD, Golightly YM (2015) State of the evidence. Curr Opin Rheumatol 27:276\u2013283. https:\/\/doi.org\/10.1097\/bor.0000000000000161","journal-title":"Curr Opin Rheumatol"},{"key":"4071_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.5435\/00124635-201007000-00003","volume":"18","author":"BT Feeley","year":"2010","unstructured":"Feeley BT, Gallo RA, Sherman S, Williams RJ (2010) Management of osteoarthritis of the knee in the active patient. J Am Acad Orthop Surg 18:406\u2013416. https:\/\/doi.org\/10.5435\/00124635-201007000-00003","journal-title":"J Am Acad Orthop Surg"},{"key":"4071_CR7","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1747946","author":"L Wild","year":"2022","unstructured":"Wild L et al (2022) Surgical outcomes and analysis of quality of life following knee arthroplasty in very elderly patients. J Knee Surg. https:\/\/doi.org\/10.1055\/s-0042-1747946","journal-title":"J Knee Surg"},{"issue":"Suppl 1","key":"4071_CR8","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.5435\/jaaos-d-16-00638","volume":"25","author":"C MacLean","year":"2017","unstructured":"MacLean C (2017) Value-based purchasing for osteoarthritis and total knee arthroplasty: what role for patient-reported outcomes? J Am Acad Orthop Surg 25(Suppl 1):S55-s59. https:\/\/doi.org\/10.5435\/jaaos-d-16-00638","journal-title":"J Am Acad Orthop Surg"},{"key":"4071_CR9","doi-asserted-by":"publisher","first-page":"e000332","DOI":"10.1136\/bmjopen-2011-000332","volume":"2","author":"H Dakin","year":"2012","unstructured":"Dakin H, Gray A, Fitzpatrick R, Maclennan G, Murray D (2012) Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. BMJ Open 2:e000332. https:\/\/doi.org\/10.1136\/bmjopen-2011-000332","journal-title":"BMJ Open"},{"key":"4071_CR10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1055\/s-0039-1688962","volume":"33","author":"WL Dai","year":"2020","unstructured":"Dai WL, Lin ZM, Shi ZJ, Wang J (2020) Venous thromboembolic events after total knee arthroplasty: which patients are at a high risk? J Knee Surg 33:947\u2013957. https:\/\/doi.org\/10.1055\/s-0039-1688962","journal-title":"J Knee Surg"},{"key":"4071_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00063198-200209000-00004","volume":"8","author":"RH White","year":"2002","unstructured":"White RH, Henderson MC (2002) Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 8:365\u2013371. https:\/\/doi.org\/10.1097\/00063198-200209000-00004","journal-title":"Curr Opin Pulm Med"},{"key":"4071_CR12","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.arth.2016.04.004","volume":"31","author":"VV An","year":"2016","unstructured":"An VV, Phan K, Levy YD, Bruce WJ (2016) Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplast 31:2608\u20132616. https:\/\/doi.org\/10.1016\/j.arth.2016.04.004","journal-title":"J Arthroplast"},{"key":"4071_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1712746","volume":"378","author":"DR Anderson","year":"2018","unstructured":"Anderson DR et al (2018) Aspirin or rivaroxaban for VTE Prophylaxis after hip or knee arthroplasty. N Engl J Med 378:699\u2013707. https:\/\/doi.org\/10.1056\/NEJMoa1712746","journal-title":"N Engl J Med"},{"key":"4071_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12:464\u2013474. https:\/\/doi.org\/10.1038\/nrcardio.2015.83","journal-title":"Nat Rev Cardiol"},{"key":"4071_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5694\/j.1326-5377.2005.tb06643.x","volume":"182","author":"RF O'Reilly","year":"2005","unstructured":"O\u2019Reilly RF, Burgess IA, Zicat B (2005) The prevalence of venous thromboembolism after hip and knee replacement surgery. Med J Aust 182:154\u2013159. https:\/\/doi.org\/10.5694\/j.1326-5377.2005.tb06643.x","journal-title":"Med J Aust"},{"key":"4071_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3349\/ymj.2015.56.1.139","volume":"56","author":"SY Lee","year":"2015","unstructured":"Lee SY et al (2015) Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J 56:139\u2013145. https:\/\/doi.org\/10.3349\/ymj.2015.56.1.139","journal-title":"Yonsei Med J"},{"key":"4071_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1055\/s-0037-1616243","volume":"86","author":"JA Heit","year":"2001","unstructured":"Heit JA et al (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452\u2013463","journal-title":"Thromb Haemost"},{"key":"4071_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/corr.0000000000000615","volume":"477","author":"M Sloan","year":"2019","unstructured":"Sloan M, Sheth N, Lee GC (2019) Is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study. Clin Orthop Relat Res 477:523\u2013532. https:\/\/doi.org\/10.1097\/corr.0000000000000615","journal-title":"Clin Orthop Relat Res"},{"key":"4071_CR19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/s0025-6196(11)61526-7","volume":"80","author":"AK Jaffer","year":"2005","unstructured":"Jaffer AK et al (2005) Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. Mayo Clin Proc 80:732\u2013738. https:\/\/doi.org\/10.1016\/s0025-6196(11)61526-7","journal-title":"Mayo Clin Proc"},{"key":"4071_CR20","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00402-015-2208-8","volume":"135","author":"J Zhang","year":"2015","unstructured":"Zhang J, Chen Z, Zheng J, Breusch SJ, Tian J (2015) Risk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysis. Arch Orthop Trauma Surg 135:759\u2013772. https:\/\/doi.org\/10.1007\/s00402-015-2208-8","journal-title":"Arch Orthop Trauma Surg"},{"key":"4071_CR21","first-page":"95","volume":"9","author":"BS Gathof","year":"2004","unstructured":"Gathof BS, Picker SM, Rojo J (2004) Epidemiology, etiology and diagnosis of venous thrombosis. Eur J Med Res 9:95\u2013103","journal-title":"Eur J Med Res"},{"key":"4071_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-2001-14668","volume":"1","author":"C Kearon","year":"2001","unstructured":"Kearon C (2001) Epidemiology of venous thromboembolism. Semin Vasc Med 1:7\u201326. https:\/\/doi.org\/10.1055\/s-2001-14668","journal-title":"Semin Vasc Med"},{"key":"4071_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.5694\/mja2.50201","volume":"210","author":"PC Kruger","year":"2019","unstructured":"Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ (2019) Deep vein thrombosis: update on diagnosis and management. Med J Aust 210:516\u2013524. https:\/\/doi.org\/10.5694\/mja2.50201","journal-title":"Med J Aust"},{"key":"4071_CR24","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/bloodadvances.2018024828","volume":"2","author":"W Lim","year":"2018","unstructured":"Lim W et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv 2:3226\u20133256. https:\/\/doi.org\/10.1182\/bloodadvances.2018024828","journal-title":"Blood Adv"},{"key":"4071_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.artd.2018.02.014","volume":"4","author":"A Shahi","year":"2018","unstructured":"Shahi A et al (2018) What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients? Arthroplast Today 4:343\u2013347. https:\/\/doi.org\/10.1016\/j.artd.2018.02.014","journal-title":"Arthroplast Today"},{"key":"4071_CR26","doi-asserted-by":"publisher","first-page":"22440","DOI":"10.1038\/s41598-020-79490-w","volume":"10","author":"K Keller","year":"2020","unstructured":"Keller K et al (2020) Venous thromboembolism in patients hospitalized for knee joint replacement surgery. Sci Rep 10:22440. https:\/\/doi.org\/10.1038\/s41598-020-79490-w","journal-title":"Sci Rep"},{"key":"4071_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.knee.2017.05.021","volume":"24","author":"C Quah","year":"2017","unstructured":"Quah C, Bayley E, Bhamber N, Howard P (2017) Fatal pulmonary embolism following elective total knee replacement using aspirin in multi-modal prophylaxis\u2014a 12\u00a0year study. Knee 24:1187\u20131190. https:\/\/doi.org\/10.1016\/j.knee.2017.05.021","journal-title":"Knee"},{"key":"4071_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1741-7015-12-39","volume":"12","author":"S Gudipati","year":"2014","unstructured":"Gudipati S et al (2014) A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients. BMC Med 12:39. https:\/\/doi.org\/10.1186\/1741-7015-12-39","journal-title":"BMC Med"},{"key":"4071_CR29","doi-asserted-by":"publisher","first-page":"132s","DOI":"10.1378\/chest.119.1_suppl.132s","volume":"119","author":"WH Geerts","year":"2001","unstructured":"Geerts WH et al (2001) Prevention of venous thromboembolism. Chest 119:132s\u2013175s. https:\/\/doi.org\/10.1378\/chest.119.1_suppl.132s","journal-title":"Chest"},{"key":"4071_CR30","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/archinte.1993.00410190057007","volume":"153","author":"DN Mohr","year":"1993","unstructured":"Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM (1993) Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med 153:2221\u20132228","journal-title":"Arch Intern Med"},{"key":"4071_CR31","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765\u20132775. https:\/\/doi.org\/10.1056\/NEJMoa0800374","journal-title":"N Engl J Med"},{"key":"4071_CR32","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.otsr.2020.02.026","volume":"106","author":"JY Jenny","year":"2020","unstructured":"Jenny JY et al (2020) Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program. Orthop Traumatol Surg Res 106:1533\u20131538. https:\/\/doi.org\/10.1016\/j.otsr.2020.02.026","journal-title":"Orthop Traumatol Surg Res"},{"key":"4071_CR33","first-page":"1093","volume":"31","author":"W Xu","year":"2018","unstructured":"Xu W, Zhang T, Yang Z, Nie L (2018) Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation. Pak J Pharm Sci 31:1093\u20131097","journal-title":"Pak J Pharm Sci"},{"key":"4071_CR34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.12659\/msm.900059","volume":"23","author":"J Xie","year":"2017","unstructured":"Xie J, Ma J, Huang Q, Yue C, Pei F (2017) Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: a pilot study. Med Sci Monit 23:704\u2013711. https:\/\/doi.org\/10.12659\/msm.900059","journal-title":"Med Sci Monit"},{"key":"4071_CR35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/s0140-6736(09)60734-0","volume":"373","author":"AG Turpie","year":"2009","unstructured":"Turpie AG et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673\u20131680. https:\/\/doi.org\/10.1016\/s0140-6736(09)60734-0","journal-title":"Lancet"},{"key":"4071_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00590-019-02365-y","volume":"29","author":"V Yuenyongviwat","year":"2019","unstructured":"Yuenyongviwat V et al (2019) Aspirin versus rivaroxaban in postoperative bleeding after total knee arthroplasty: a retrospective case-matched study. Eur J Orthop Surg Traumatol 29:877\u2013881. https:\/\/doi.org\/10.1007\/s00590-019-02365-y","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"4071_CR37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/MBC.0000000000000121","volume":"25","author":"Y Zou","year":"2014","unstructured":"Zou Y, Tian S, Wang Y, Sun K (2014) Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis 25:660\u2013664. https:\/\/doi.org\/10.1097\/MBC.0000000000000121","journal-title":"Blood Coagul Fibrinolysis"},{"key":"4071_CR38","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","volume":"134","author":"T Fuji","year":"2014","unstructured":"Fuji T et al (2014) Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 134:1198\u20131204. https:\/\/doi.org\/10.1016\/j.thromres.2014.09.011","journal-title":"Thromb Res"},{"issue":"11","key":"4071_CR39","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","volume":"5","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE\u2010MODEL randomized trial. J Thromb Haemost 5(11):2178\u20132185. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02748.x","journal-title":"J Thromb Haemost"},{"issue":"1","key":"4071_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.rboe.2017.11.007","volume":"53","author":"JL Colleoni","year":"2018","unstructured":"Colleoni JL et al (2018) Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban. Rev Bras de Ortop 53(1):22\u201327. https:\/\/doi.org\/10.1016\/j.rboe.2017.11.007","journal-title":"Rev Bras de Ortop"},{"issue":"18","key":"4071_CR41","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa011099","volume":"345","author":"KA Bauer","year":"2001","unstructured":"Bauer KA, Eriksson BI, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. New Engl J Med 345(18):1305\u20131310. https:\/\/doi.org\/10.1056\/NEJMoa011099","journal-title":"New Engl J Med"},{"key":"4071_CR42","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3760\/cma.j.issn.0366-6999.20132175","volume":"127","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Du H, Liu J, Zhou Y (2014) Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chin Med J (Engl) 127:2201\u20132205","journal-title":"Chin Med J (Engl)"},{"key":"4071_CR43","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","volume":"5","author":"MR Lassen","year":"2007","unstructured":"Lassen MR et al (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368\u20132375. https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02764.x","journal-title":"J Thromb Haemost"},{"key":"4071_CR44","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1056\/NEJMoa076016","volume":"358","author":"MR Lassen","year":"2008","unstructured":"Lassen MR et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776\u20132786. https:\/\/doi.org\/10.1056\/NEJMoa076016","journal-title":"N Engl J Med"},{"key":"4071_CR45","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594\u2013604. https:\/\/doi.org\/10.1056\/NEJMoa0810773","journal-title":"N Engl J Med"},{"key":"4071_CR46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/s0140-6736(09)62125-5","volume":"375","author":"MR Lassen","year":"2010","unstructured":"Lassen MR et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807\u2013815. https:\/\/doi.org\/10.1016\/s0140-6736(09)62125-5","journal-title":"Lancet"},{"issue":"7","key":"4071_CR47","doi-asserted-by":"publisher","first-page":"619","DOI":"10.7326\/0003-4819-124-7-199604010-00001","volume":"124","author":"JR Leclerc","year":"1996","unstructured":"Leclerc JR et al (1996) Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 124(7):619\u2013626. https:\/\/doi.org\/10.7326\/0003-4819-124-7-199604010-00001","journal-title":"Ann Intern Med"},{"key":"4071_CR48","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/jth.12109","volume":"11","author":"GF Pineo","year":"2013","unstructured":"Pineo GF et al (2013) Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost 11:444\u2013451. https:\/\/doi.org\/10.1111\/jth.12109","journal-title":"J Thromb Haemost"},{"issue":"11","key":"4071_CR49","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","volume":"3","author":"AG Turpie","year":"2005","unstructured":"Turpie AG et al (2005) BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3(11):2479\u20132486. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01602.x","journal-title":"J Thromb Haemost"},{"key":"4071_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","volume":"24","author":"JS Ginsberg","year":"2009","unstructured":"Ginsberg JS et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplast 24:1\u20139. https:\/\/doi.org\/10.1016\/j.arth.2008.01.132","journal-title":"J Arthroplast"},{"key":"4071_CR51","unstructured":"Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, Moschetti I, Phillips B, Thornton H, Goddard O, Hodgkinson M (2011) The 2011 Oxford CEBM Levels of evidence. Oxford Centre for evidence-based medicine. Available at https:\/\/www.cebm.net\/index.aspx?o=5653"},{"key":"4071_CR52","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"4071_CR53","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M et al (2019) Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"4071_CR54","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2021) Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane 2021. Available from www.training.cochrane.org\/handbook. Accessed on February 2022"},{"key":"4071_CR55","doi-asserted-by":"publisher","first-page":"CD007557","DOI":"10.1002\/14651858.CD007557.pub3","volume":"4","author":"DR Junqueira","year":"2017","unstructured":"Junqueira DR, Zorzela LM, Perini E (2017) Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 4:CD007557. https:\/\/doi.org\/10.1002\/14651858.CD007557.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"4071_CR56","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.11-2404","volume":"141","author":"Y Falck-Ytter","year":"2012","unstructured":"Falck-Ytter Y et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 141:e278S-e325S. https:\/\/doi.org\/10.1378\/chest.11-2404","journal-title":"Chest"},{"key":"4071_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11239-013-0889-9","volume":"35","author":"CW Francis","year":"2013","unstructured":"Francis CW (2013) Prevention of VTE in patients having major orthopedic surgery. J Thromb Thromb 35:359\u2013367. https:\/\/doi.org\/10.1007\/s11239-013-0889-9","journal-title":"J Thromb Thromb"},{"issue":"18","key":"4071_CR58","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa011100","volume":"345","author":"BI Eriksson","year":"2001","unstructured":"Eriksson BI, Bauer KA, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. New Engl J Med 345(18):1298\u20131304. https:\/\/doi.org\/10.1056\/NEJMoa011100","journal-title":"New Engl J Med"},{"key":"4071_CR59","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/s0140-6736(02)08652-x","volume":"359","author":"MR Lassen","year":"2002","unstructured":"Lassen MR, Bauer KA, Eriksson BI, Turpie AG (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359:1715\u20131720. https:\/\/doi.org\/10.1016\/s0140-6736(02)08652-x","journal-title":"Lancet"},{"key":"4071_CR60","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2519\/jospt.2002.32.6.260","volume":"32","author":"E Trudelle-Jackson","year":"2002","unstructured":"Trudelle-Jackson E, Emerson R, Smith S (2002) Outcomes of total hip arthroplasty: a study of patients one year postsurgery. J Orthop Sports Phys Ther 32:260\u2013267. https:\/\/doi.org\/10.2519\/jospt.2002.32.6.260","journal-title":"J Orthop Sports Phys Ther"},{"key":"4071_CR61","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1111\/j.1538-7836.2003.00494.x","volume":"1","author":"BI Eriksson","year":"2003","unstructured":"Eriksson BI et al (2003) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1:2490\u20132496. https:\/\/doi.org\/10.1111\/j.1538-7836.2003.00494.x","journal-title":"J Thromb Haemost"},{"key":"4071_CR62","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","volume":"4","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI et al (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121\u2013128. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01657.x","journal-title":"J Thromb Haemost"},{"key":"4071_CR63","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","volume":"114","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI et al (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114:2374\u20132381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.642074","journal-title":"Circulation"},{"key":"4071_CR64","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","volume":"120","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI et al (2007) Dose-escalation study of rivaroxaban (BAY 59-7939)\u2014an oral, direct Factor Xa inhibitor\u2014for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685\u2013693. https:\/\/doi.org\/10.1016\/j.thromres.2006.12.025","journal-title":"Thromb Res"},{"key":"4071_CR65","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(08)60880-6","journal-title":"Lancet"},{"key":"4071_CR66","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","volume":"66","author":"YB Cao","year":"2010","unstructured":"Cao YB, Zhang JD, Shen H, Jiang YY (2010) Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 66:1099\u20131108. https:\/\/doi.org\/10.1007\/s00228-010-0889-z","journal-title":"Eur J Clin Pharmacol"},{"key":"4071_CR67","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"MR Lassen","year":"2010","unstructured":"Lassen MR et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487\u20132498. https:\/\/doi.org\/10.1056\/NEJMoa1006885","journal-title":"N Engl J Med"},{"key":"4071_CR68","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1160\/TH10-10-0679","volume":"105","author":"BI Eriksson","year":"2011","unstructured":"Eriksson BI et al (2011) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 105:721\u2013729. https:\/\/doi.org\/10.1160\/TH10-10-0679","journal-title":"Thromb Haemost"},{"key":"4071_CR69","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1302\/0301-620X.94B2.27850","volume":"94","author":"GE Raskob","year":"2012","unstructured":"Raskob GE et al (2012) Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 94:257\u2013264. https:\/\/doi.org\/10.1302\/0301-620X.94B2.27850","journal-title":"J Bone Joint Surg Br"},{"key":"4071_CR70","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.arth.2014.05.029","volume":"29","author":"T Fuji","year":"2014","unstructured":"Fuji T et al (2014) Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 29:2439\u20132446. https:\/\/doi.org\/10.1016\/j.arth.2014.05.029","journal-title":"J Arthroplasty"},{"key":"4071_CR71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12959-015-0057-x","volume":"13","author":"T Fuji","year":"2015","unstructured":"Fuji T et al (2015) Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J 13:27. https:\/\/doi.org\/10.1186\/s12959-015-0057-x","journal-title":"Thromb J"},{"key":"4071_CR72","unstructured":"Jupalli A, Iqbal AM (2022) In StatPearls (StatPearls Publishing Copyright\u00a9 2022, StatPearls Publishing LLC., 2022)"},{"key":"4071_CR73","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","volume":"42","author":"J Fareed","year":"2003","unstructured":"Fareed J et al (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin\u202f: implications for clinical practice. Clin Pharmacokinet 42:1043\u20131057. https:\/\/doi.org\/10.2165\/00003088-200342120-00003","journal-title":"Clin Pharmacokinet"},{"key":"4071_CR74","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58:1265\u20131279. https:\/\/doi.org\/10.1007\/s40262-019-00775-z","journal-title":"Clin Pharmacokinet"},{"key":"4071_CR75","doi-asserted-by":"publisher","first-page":"636","DOI":"10.2174\/1389200218666170518165443","volume":"18","author":"T Kvasnicka","year":"2017","unstructured":"Kvasnicka T et al (2017) Rivaroxaban\u2014metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 18:636\u2013642. https:\/\/doi.org\/10.2174\/1389200218666170518165443","journal-title":"Curr Drug Metab"},{"key":"4071_CR76","unstructured":"Patel S, Singh R, Preuss CV, Patel N (2022) In StatPearls (StatPearls Publishing Copyright\u00a9 2022, StatPearls Publishing LLC., 2022)."},{"key":"4071_CR77","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3174\/ajnr.A3000","volume":"33","author":"J Comin","year":"2012","unstructured":"Comin J, Kallmes DF (2012) Dabigatran (Pradaxa). AJNR Am J Neuroradiol 33:426\u2013428. https:\/\/doi.org\/10.3174\/ajnr.A3000","journal-title":"AJNR Am J Neuroradiol"},{"key":"4071_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-9560-2-1","volume":"2","author":"R Altman","year":"2004","unstructured":"Altman R, Luciardi HL, Muntaner J, Herrera RN (2004) The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2:1. https:\/\/doi.org\/10.1186\/1477-9560-2-1","journal-title":"Thromb J"},{"key":"4071_CR79","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","volume":"116","author":"MA Crowther","year":"2002","unstructured":"Crowther MA, Berry LR, Monagle PT, Chan AK (2002) Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116:178\u2013186. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03233.x","journal-title":"Br J Haematol"}],"container-title":["European Journal of Orthopaedic Surgery & Traumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-024-04071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00590-024-04071-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-024-04071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T21:05:43Z","timestamp":1725570343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00590-024-04071-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":79,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["4071"],"URL":"https:\/\/doi.org\/10.1007\/s00590-024-04071-w","relation":{},"ISSN":["1432-1068"],"issn-type":[{"value":"1432-1068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]},"assertion":[{"value":"25 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study complies with ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}